These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 20026449)
1. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection. Hickey DK; Aldwell FE; Beagley KW Vaccine; 2010 Feb; 28(7):1668-72. PubMed ID: 20026449 [TBL] [Abstract][Full Text] [Related]
2. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Hickey DK; Aldwell FE; Beagley KW Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810 [TBL] [Abstract][Full Text] [Related]
3. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. Hansen J; Jensen KT; Follmann F; Agger EM; Theisen M; Andersen P J Infect Dis; 2008 Sep; 198(5):758-67. PubMed ID: 18652549 [TBL] [Abstract][Full Text] [Related]
4. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection. Skelding KA; Hickey DK; Horvat JC; Bao S; Roberts KG; Finnie JM; Hansbro PM; Beagley KW Vaccine; 2006 Jan; 24(3):355-66. PubMed ID: 16153755 [TBL] [Abstract][Full Text] [Related]
5. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Hickey DK; Aldwell FE; Tan ZY; Bao S; Beagley KW Vaccine; 2009 Nov; 27(50):6983-90. PubMed ID: 19800441 [TBL] [Abstract][Full Text] [Related]
6. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Pal S; Peterson EM; Rappuoli R; Ratti G; de la Maza LM Vaccine; 2006 Feb; 24(6):766-75. PubMed ID: 16199110 [TBL] [Abstract][Full Text] [Related]
7. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model. Andrew DW; Hafner LM; Beagley KW; Timms P J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018 [TBL] [Abstract][Full Text] [Related]
8. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Pal S; Tatarenkova OV; de la Maza LM Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798 [TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987 [TBL] [Abstract][Full Text] [Related]
12. The Verma R; Sahu R; Dixit S; Duncan SA; Giambartolomei GH; Singh SR; Dennis VA Front Immunol; 2018; 9():2369. PubMed ID: 30374357 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. Ifere GO; He Q; Igietseme JU; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Eko FO J Microbiol Immunol Infect; 2007 Jun; 40(3):188-200. PubMed ID: 17639158 [TBL] [Abstract][Full Text] [Related]
14. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. Schautteet K; Stuyven E; Beeckman DS; Van Acker S; Carlon M; Chiers K; Cox E; Vanrompay D Vaccine; 2011 Feb; 29(7):1399-407. PubMed ID: 21195805 [TBL] [Abstract][Full Text] [Related]
15. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442 [TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Cong Y; Jupelli M; Guentzel MN; Zhong G; Murthy AK; Arulanandam BP Vaccine; 2007 May; 25(19):3773-80. PubMed ID: 17349723 [TBL] [Abstract][Full Text] [Related]
17. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585 [TBL] [Abstract][Full Text] [Related]
18. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089 [TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate. Hickey DK; Jones RC; Bao S; Blake AE; Skelding KA; Berry LJ; Beagley KW Vaccine; 2004 Oct; 22(31-32):4306-15. PubMed ID: 15474723 [TBL] [Abstract][Full Text] [Related]
20. Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. Cunningham KA; Carey AJ; Hafner L; Timms P; Beagley KW Am J Reprod Immunol; 2011 Feb; 65(2):118-26. PubMed ID: 20618179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]